We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genomic Testing in NICU Reduces Missed Diagnoses

By LabMedica International staff writers
Posted on 01 Jul 2025

There remains a significant shortfall in the current system of neonatal care—many critically ill newborns, especially those from underserved backgrounds, are not being offered genetic testing, resulting in missed diagnoses and lost chances for precision treatment. More...

A study published in the American Journal of Human Genetics now highlights how the broad adoption of rapid genome sequencing (rGS) reveals that more critically ill infants should undergo testing to minimize undetected genetic conditions and support equitable care at a time when these patients are most vulnerable.

The study, called Seqfirst-neo, was conducted through a collaboration between Seattle Children’s (Seattle, WA, USA) and the University of Washington (Seattle, WA, USA). It investigated how the use of rGS in neonatal intensive care units (NICUs) can enhance diagnostic access, particularly for underrepresented groups, to reduce undiagnosed cases and improve patient outcomes. Infants qualified for rGS unless their condition was fully explained by birth or physical trauma, prematurity-related complications, infection, or if they already had a clear pre-existing genetic diagnosis (PrGD). Out of 408 NICU infants reviewed, 59% were deemed eligible for rGS. Among these, 126 infants were placed in the interventional group (IG) and received rGS, while the remainder continued with the standard diagnostic approach. According to Seqfirst-neo’s results, at least 60% of infants in Level IV NICUs should be undergoing rGS. With roughly 400,000 NICU admissions each year across 800 NICUs in the U.S., many thousands of infants with genetic disorders are likely going undiagnosed due to insufficient testing access.

The study demonstrates that using basic exclusion criteria can greatly boost the number of NICU infants who receive diagnoses, speed up time to diagnosis, and improve access for diverse populations who might otherwise miss testing opportunities. These findings strongly support that wider access to genetic testing leads to significantly higher rates of PrGD, advances healthcare equity, and reduces missed diagnoses. Notably, Seqfirst-neo is the first study to employ exclusion—rather than inclusion—criteria to determine which infants in the NICU should receive genomic testing. This strategy marks a shift in clinical practice, enabling neonatologists to more easily identify candidates for testing and expand access to infants who previously would have been excluded.

“Our findings showcase that by shifting today’s standard of care to an exclusion-based model for genomic testing, we can significantly expand access, improve health outcomes, and ensure that more families receive the answers they need at the most critical times,” said Mike Bamshad, MD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Clinical Genetics Division Chief at Seattle Children’s.

“By offering genetic testing at the first unexplained issue in critically ill newborns, we have an opportunity to make diagnoses before they are old enough to experience many of the complications of their genetic disorder. This allows neonatologists and other health care providers the opportunity to introduce the most precise treatments as early as possible,” added Tara Wenger, MD, PhD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Associate Medical Director, Inpatient Service at Seattle Children’s.

Related Links:
Seattle Children’s
University of Washington


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.